Literature DB >> 2181946

Antireticulin antibody in systemic sclerosis.

T Mahmud1, M Peakman, G Senaldi, A McWhirter, C M Black, D Vergani.   

Abstract

The prevalence, immunoglobulin class, and IgG subclass of antireticulin antibody in the serum samples of 32 patients with systemic sclerosis were investigated by indirect immunofluorescence on unfixed rodent tissue. Antireticulin antibody was present in 22/32 (69%) of patients and belonged to the IgG class in 19/22 (86%), the IgA class in 13/22 (59%), and the IgM class in 6/22 (27%) of positive sera. IgG1 was the predominant subclass of IgG antireticulin antibody, occurring either alone or in association with IgG3 in 12/19 cases (63%). Thus antireticulin antibody of the IgG and IgA classes is found in most patients with systemic sclerosis. The finding of an autoantibody with reactivity for collagen-like fibres in systemic sclerosis indicates that the antibody has a potential role in the pathogenesis of the disease, and as it belongs to the IgA class this suggests that it arises in response to antigens presented to the immune system at the mucosal level.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2181946      PMCID: PMC1004016          DOI: 10.1136/ard.49.3.177

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  Antireticulin antibody: incidence and diagnostic significance.

Authors:  P P Seah; L Fry; E J Holborow; M A Rossiter; W F Doe; A F Magalhaes; A V Hoffbrand
Journal:  Gut       Date:  1973-04       Impact factor: 23.059

3.  Silver impregnation: collagenic and reticular fibers and the ground substance.

Authors:  L Valdrighi; B de C Vidal
Journal:  Ann Histochim       Date:  1971 Jan-Mar

4.  Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study.

Authors:  R Jefferis; C B Reimer; F Skvaril; G de Lange; N R Ling; J Lowe; M R Walker; D J Phillips; C H Aloisio; T W Wells
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

5.  IgG subclass distribution of autoantibodies to DNA and to nuclear ribonucleoproteins in autoimmune diseases.

Authors:  M Zouali; R Jefferis; A Eyquem
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

6.  Evaluation of a serum IgA-class reticulin antibody test for the detection of childhood celiac disease.

Authors:  M Mäki; O Hällström; T Vesikari; J K Visakorpi
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

7.  Characterization of anti-liver kidney microsomal antibody in childhood autoimmune chronic active hepatitis: evidence for IgG1 subclass restriction, polyclonality and non cross-reactivity with hepatocyte surface antigens.

Authors:  M Peakman; A Lobo-Yeo; G Mieli-Vergani; E T Davies; A P Mowat; D Vergani
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

8.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

10.  Ultrastructural identification of extension aminopropeptides of type I and III collagens in human skin.

Authors:  R Fleischmajer; R Timpl; L Tuderman; L Raisher; M Wiestner; J S Perlish; P N Graves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

View more
  1 in total

1.  IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves' disease.

Authors:  I Molnár; V Kaczur; A Boros; G Krajczár; C Balázs
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.